Skip to main content
    O

    Oric Pharmaceuticals Inc (ORIC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.77
    +1.18 (+10.18%)

    Market Cap: $1.20B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(13/26)
    Avg Surprise
    -6.07%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.38
    Range$-0.45 - $-0.32
    13 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.37-1.9%
    60d ago$-0.37-2.0%
    30d ago$-0.37-1.4%
    7d ago$-0.38-0.7%
    Current$-0.38
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.43
    Range$-0.58 - $-0.19
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.43---
    Sep 26EST
    		-$-0.38---
    Jun 26
    Reported Aug 3
    		$-0.38$-0.36-5.56%Miss+19.1%
    Mar 26
    Reported May 4
    		$-0.34$-0.32-6.25%Miss+19.0%
    Dec 25
    Reported Feb 23
    		$-0.30$-0.37+18.23%Beat+41.2%
    Sep 25
    Reported Nov 13
    		$-0.33$-0.40+17.50%Beat+32.7%
    Jun 25
    Reported Aug 12
    		$-0.47$-0.44-6.82%Miss-4.4%
    Mar 25
    Reported May 5
    		$-0.42$-0.50+16.00%Beat-13.5%
    Dec 24
    Reported Feb 18
    		$-0.51$-0.51-0.31%Miss-4.1%
    Sep 24
    Reported Nov 12
    		$-0.49$-0.47-4.26%Miss-11.4%
    Jun 24
    Reported Aug 12
    		$-0.45$-0.41-9.76%Miss+10.0%
    Mar 24
    Reported May 6
    		$-0.37$-0.43+13.95%Beat+30.2%
    Dec 23
    Reported Mar 11
    		$-0.49$-0.49+0.00%Beat+5.8%
    Sep 23
    Reported Nov 6
    		$-0.44$-0.46+4.35%Beat+30.2%
    Jun 23
    Reported Aug 10
    		$-0.50$-0.57+12.28%Beat+2.0%
    Mar 23
    Reported May 8
    		$-0.53$-0.54+1.85%Beat+10.2%
    Dec 22
    Reported Mar 16
    		$-0.52$-0.54+3.70%Beat+10.3%
    Sep 22
    Reported Nov 7
    		$-0.63$-0.55-14.55%Miss-34.0%
    Jun 22
    Reported Aug 11
    		$-0.51$-0.60+15.00%Beat+10.5%
    Mar 22
    Reported May 9
    		$-0.59$-0.57-3.51%Miss-31.1%
    Dec 21
    Reported Mar 21
    		$-0.58$-0.57-1.75%Miss+31.0%
    Sep 21
    Reported Nov 8
    		$-0.47$-0.58+18.97%Beat+44.0%
    Jun 21
    Reported Aug 10
    		$-0.57$-0.49-16.33%Miss-11.8%
    Mar 21
    Reported May 6
    		$-0.45$-0.48+6.25%Beat-7.1%
    Dec 20
    Reported Mar 23
    		$-0.84$-0.46-82.61%Miss-950.0%
    Sep 20
    Reported Nov 5
    		$-0.84$-0.39-115.38%Miss-
    Jun 20
    Reported Aug 5
    		$-0.51$-0.40-27.50%Miss-
    Mar 20
    Reported Apr 23
    		$-0.42$-0.46+8.70%Beat-
    Dec 19
    Reported Feb 28
    		$-0.08$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.46EV/EBITDAN/A
    Price/FCF-12.29xFCF Yield-8.14%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-39.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.19xQuick Ratio13.19x
    Trading Statistics
    Beta0.98Avg Volume1.59M
    52-Week High$14.6852-Week Low$7.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.02
    SMA 20$12.57
    SMA 50$12.98
    SMA 200$11.00
    EMA 10$12.14
    EMA 20$12.37
    EMA 50$12.39
    EMA 200$11.21

    MACD

    Line: -0.25Signal: -0.20Hist: -0.05

    ADX

    ADX: 21.4+DI: 20.9-DI: 23.3

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down80.0
    PSAR$10.93

    Bollinger Bands

    Upper Band$13.93
    Lower Band$11.21
    %B Position2160%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    53.6

    Momentum Oscillators

    Stoch %K30.2
    Stoch %D24.9
    Williams %R-42.3
    ROC (10d)2.0%
    Momentum0.25
    CCI (20d)-20.6
    MFI (14d)42.4

    Volatility Measures

    ATR (14d)$0.78(6.1%)
    StdDev (20d)0.68
    Hist Vol58.4%(High)

    Volume Flow

    VWAP$12.40
    OBV828.9K
    AD Line-6.1M
    CMF (20d)-0.007

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio1.0x
    VWMA (20d)$12.62

    Pivot Points

    R3$12.52
    R2$12.18
    R1$11.88
    Pivot Point$11.54
    S1$11.25
    S2$10.91
    S3$10.61

    Advanced Oscillators

    TSI-12.46
    Ultimate Osc53.5
    KST-68.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.07M$0$0$0$1.54M$0
    Cost of Revenue$0$0$320,000$0$0$0$304,000$0$0$0$263,000$0
    Gross Profit$0$0$-320,000$0$0$0$-304,000$0$0$0$-263,000$0
    Operating Expenses$45.30M$39.62M$34.55M$36.67M$39.06M$32.72M$39.57M$38.32M$36.02M$28.99M$31.43M$28.68M
    R&D$36.30M$31.44M$25.86M$28.77M$30.55M$24.64M$31.97M$31.20M$28.94M$21.96M$24.48M$22.39M
    SG&A$9.00M$8.18M$8.70M$7.90M$8.52M$8.08M$7.60M$7.12M$7.08M$7.03M$6.95M$6.29M
    Operating Income$-45,296,000$-39,619,000$-34,551,000$-36,671,000$-39,064,000$-32,718,000$-39,570,000$-38,318,000$-36,017,000$-28,990,000$-31,428,000$-28,682,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-41,492,000$-35,767,000$-30,505,000$-32,587,000$-36,355,000$-30,021,000$-36,307,000$-34,566,000$-31,963,000$-25,011,000$-28,330,000$-25,478,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-41,492,000$-35,767,000$-30,505,000$-32,587,000$-36,355,000$-30,021,000$-36,307,000$-34,566,000$-31,963,000$-25,011,000$-28,330,000$-25,478,000
    EBITDA$-44,741,000$-39,187,000$-34,471,000$-36,970,000$-39,345,000$-33,298,000$-40,900,000$-39,994,000$-38,041,000$-30,956,000$-33,288,000$-30,347,000
    EBIT$-45,296,000$-39,619,000$-34,551,000$-36,671,000$-39,064,000$-32,718,000$-39,570,000$-38,318,000$-36,017,000$-28,990,000$-31,428,000$-28,682,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ORIC

    News

    Oric Pharmaceuticals Q3 2026 Earnings Date and Estimates

    Oric Pharmaceuticals (ORIC) is projected to release its Q3 2026 earnings on Thursday, November 12, 2026, after the market closes, with a conference call scheduled for November 13, 2026...

    MarketBeat•10/15/26•Neutral

    JPMorgan raises target for ORIC Pharmaceuticals stock to USD 26.00

    JPMorgan has increased its price target for ORIC Pharmaceuticals (ORIC) stock from USD 23.00 to USD 26.00, maintaining an "Overweight" rating. Despite a recent quarterly loss of USD 0.38 per share...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Oric Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $26.00

    JPMorgan Chase & Co. has raised its price target for Oric Pharmaceuticals (NASDAQ:ORIC) to $26.00 from $23.00, maintaining an "overweight" rating...

    MarketBeat•10/14/26•Somewhat-Bullish

    ORIC Maintained by JP Morgan -- Price Target Raised to $26.00

    JP Morgan has maintained an Overweight rating on ORIC Pharmaceuticals, raising its price target from $23.00 to $26.00...

    GuruFocus•10/14/26•Somewhat-Bullish

    Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock By Investing.com

    Richard A. Heyman, a director at Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), sold 6,700 shares of the company’s common stock for a total of $86,524. The sales were conducted under a Rule 10b5-1 trading plan and followed...

    Investing.com South Africa•10/13/26•Neutral

    ORIC Valuation and Fair Value

    P/E
    -9.5x
    P/FCF
    -12.3x
    P/B
    3.6x
    See GNG's fair value

    ORIC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -39.8%
    FCF yield
    -8.1%

    ORIC Competitors

    CompanyTicker
    Tourmaline Bio Inc.TRML
    CareCloud, Inc.CCLDO
    InnovAge Holding CorpINNV
    Cronos Group IncCRON
    Syndax Pharmaceuticals IncSNDX
    Goodrx Holdings IncGDRX
    Inhibrx Biosciences, Inc.INBX
    Iradimed CoIRMD

    Sector: Healthcare

    ORIC Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    2
    Buy
    12
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ORIC Bull Case vs Bear Case

    Bull case

    • 93.3% of ORIC's analyst ratings are Buy or Strong Buy.

    Bear case

    • ORIC beat EPS estimates in 37.5% of its last 8 reported quarters.

    ORIC Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    3.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.38
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About ORIC

    Does ORIC pay dividends?

    Oric Pharmaceuticals Inc (ORIC) does not currently pay a regular dividend.

    What is ORIC's market cap?

    Oric Pharmaceuticals Inc (ORIC) has a market capitalization of $1.20B with a current stock price of $12.77.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In